Home UrgoStart Plus Range UrgoKTwo UrgoClean Ag UrgoTul Silver UrgoTul Family More THE ONLY DRESSING PROVEN TO REDUCE HEALING TIME OF LEG ULCERS, DIABETIC FOOT ULCERS AND PRESSURE ULCERS. WHY USE THE URGOSTART PLUS RANGE? All UrgoStart dressings are now recommended by NICE for venous leg ulcers and diabetic foot ulcers, giving you confidence in the dressing suitability for your patients (7) With its unique TLC-NOSF* Healing Matrix (NOSF* impregnated in a TLC healing matrix) UrgoStart is the only local treatment proven to reduce healing time (1,2,3,4) The sooner the UrgoStart range is initiated the better the healing outcomes for the patient (5) UrgoStart range significantly improves patients' quality of life (2,3) UrgoStart Plus range acts from Day 1 to complete healing, whatever the wound healing phase, simplifying treatment for clinicians and saving costs for healthcare systems (6) Discover what NICE says about UrgoStart range URGOSTART PLUS RANGE PROPERTIES Absorption of exudate Creation and maintenance of a moist wound environment that promotes healing Atraumatic & pain free removal Respect of peri-wound skin Very conformable and easy to reposition INDICATIONS UrgoStart Plus is indicated for all stages (from the desloughing stage to complete healing) of exuding wounds including leg ulcers, diabetic foot ulcers, pressure ulcers, and long standing acute wounds. Instructions for use URGOSTART IS AVAILABLE IN A FULL RANGE FOR YOUR PATIENTS UrgoStart Plus Pad and UrgoStart Plus Border also contain poly-absorbent fibres which bind, trap and retain exudate, slough and debris present in the wound, keeping it clean throughout healing. Sizes and ordering codes CONTRAINDICATIONS In order not to delay any optimal treatment, UrgoStart treatment range is contraindicated in cancerous wounds and fistula wounds which may reveal a deep abscess Do not use when there is a known sensitivity to UrgoStart dressings UrgoStart Plus Pad and UrgoStart Plus Border facilitate the management of minor bleeding wounds. However, they should not be used as a surgical sponge for heavily bleeding wound *NOSF (Nano OligoSaccharide Factor) = KSOS (potassium sucrose octasulfate) References (1) Münter KC, Meaume S, Augustin M, Senet P, Kérihuel J.C. The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings. J Wound Care. 2017 Feb; 26 (Sup2): S4-S15. Erratum in: J Wound Care. 2017 Mar 2; 26(3): 153. (2) Meaume S. et al., Quality of life in patients with leg ulcers: results from CHALLENGE, a double-blind randomized controlled trial. Journal of Wound Care. 2017; 26 (7): 368-379. (3) Meaume S. et al., A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-OligoSaccharide Factor wound dressing in the local management of venous leg ulcers. Wound Repair Regen. 2012; 20: 4, 500–511. (4) Edmonds M, Lázaro-Martínez JL, Alfayate-García JM, Martini J, Petit JM, Rayman G, Lobmann R, Uccioli L, Sauvadet A, Bohbot S, Kerihuel JC, Piaggesi A. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018 Mar;6(3):186-196. (5) Lazaro et al . Optimal wound closure of diabetic foot ulcers with early initiation of TLC-NOSF treatment: post-hoc analysis of Explorer.JWC VOL 28, Nº 6 , JUNE 2019. (6) An Economic Evaluation of UrgoStart® for Patients with Chronic Leg Ulcers in the United Kingdom. York University. Data on file. Urgo, 2011. (7) NICE medical technology guidance 42: UrgoStart for treating diabetic foot ulcers and leg ulcers, https://www.nice.org.uk/guidance/mtg42 Find out more about each of our life-changing solutions: UrgoStart Plus Range UrgoKTwo UrgoClean Ag The UrgoTul Family ©2020 by Urgo Medical UK. Urgo Limited - Sullington Road - Shepshed - Loughborough LE12 9JG - Tel. : 0330 128 0898 - Fax : 01509 650 898 Anti-Slavery and Human Trafficking Statement